Latest Agomab Therapeutics News & Updates

See the latest news and media coverage for Agomab. We track all announcements, press releases, and industry mentions in real time, all in one place.

Agomab Therapeutics (Agomab)

Clinical-stage biopharmaceutical company developing fibrosis therapies

agomab.com

Headquarters: Antwerp, Belgium
Founded year: 2017
Company type: Private company
Number of employees: 70–200

Last updated Today

Latest news about Agomab Therapeutics (Agomab)

In short: Agomab completed its $208 million Nasdaq IPO and reported positive clinical data for its lead programs in Crohn’s disease and pulmonary fibrosis.

Company announcements

April 23 Agomab

Agomab reports full year 2025 financial results

It raised $208M in Feb 2026, held €116.5M year-end cash, expects runway into H1 2029, and plans Phase 2 starts with topline readouts in H2 2026.

March 26 Agomab

Agomab receives U.S. patent for AGMB-447

The patent covers the inhaled ALK5 inhibitor in Phase 1b for IPF, providing IP protection through 2041. CEO highlights it as a key milestone.

March 10 Agomab

Agomab Therapeutics presents positive Phase 2a results

Nature Reviews highlights their ontunisertib presentation for Fibrostenosing Crohn’s disease at ECCO'26 Congress.

February 7 Agomab

Agomab announces closing of IPO

The offering raised $200 million from 12.5 million ADSs at $16 each. ADSs trade on Nasdaq as AGMB.

Media coverage

June 4 Investing.com

Agomab prices IPO at $16 per share, aims to raise $200 million

Agomab Therapeutics NV (AGMB) priced its initial public offering at $16.00 per American Depositary Share, the Belgium-based biopharmaceutical company announced February 5.

April 23 Markets Insider

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO...

April 12 Yahoo Finance

AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447

Learn more AgomAb Therapeutics NV (NASDAQ:AGMB) is one of the 7 Best Strong Buy European Stocks to Invest In. On March 26, 2026, AgomAb Therapeutics...

March 31 American Banking News

Analyzing AgomAb Therapeutics (NASDAQ:AGMB) & Prime Medicine (NASDAQ:PRME) - American Market News

AgomAb Therapeutics (NASDAQ:AGMB – Get Free Report) and Prime Medicine (NASDAQ:PRME – Get Free Report) are both small-cap manufacturing companies, but which is the better...

Never miss news about Agomab

Track Agomab and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Agomab competitors & trending companies

Browse news for competitors to Agomab and other trending companies.